Add like
Add dislike
Add to saved papers

Role of gadolinium-enhanced magnetic resonance imaging in retroperitoneal fibrosis.

PURPOSE: To determine if the gadolinium-enhancement characteristics of magnetic resonance images (MRI) differ for acute and chronic benign retroperitoneal fibrosis (RPF).

METHOD: Seven male subjects, 3 with newly diagnosed nontreated RPF (acute group) and 4 with long-standing stable RPF (chronic group) who had been treated with steroids, ureteric stents or both, underwent MRI examinations with gadolinium enhancement. Patients in the acute group were examined again after treatment. Mean dynamic gadolinium-enhancement ratios (both dynamic and delayed) were calculated for each group.

RESULTS: The initial mean dynamic enhancement ratio for the acute group (mean 1.86, range 1.80-1.95) was significantly different (p = 0.005) from that of the chronic group (mean 1.37, range 1.26-1.61). The mean dynamic enhancement ratio for the acute group after treatment (4-8 months duration) was 1.40 (range 1.26-1.51). The mean delayed enhancement ratio (RPF/psoas muscle signal intensity) for the acute group was 1.41 (range 1.38-1.43, data from 2 patients) and for the chronic group was 1.29 (range 1.13-1.44).

CONCLUSION: Dynamic gadolinium enhancement was useful in differentiating newly diagnosed RPF from treated chronic disease and may have a role in assessing disease activity, monitoring response to treatment and detecting relapse.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.
Urinary Tract Infections: Core Curriculum 2024.American Journal of Kidney Diseases 2023 October 31

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app